With our collaboration partner Sanofi, we are developing long-acting TransCon prodrugs for the treatment of diabetes.
Our TransCon prodrugs are designed to enable safe and efficacious levels of unmodified drug and provide extended dosing profiles.
Sanofi is currently conducting preclinical studies to evaluate the safety and efficacy of various TransCon prodrug candidates for the treatment of diabetes.
Diabetes: Unmet Needs
Diabetes is a major cause of morbidity and mortality across the world. The current standard of care for diabetes often requires daily injections, and compliance and adherence to such regimens are poor. Failure to receive adequate and consistent drug levels may be associated with suboptimal treatment outcomes, including severe complications and increased mortality in diabetic patients.